Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers

[1]  M. Dunning,et al.  Genome-driven integrated classification of breast cancer validated in over 7,500 samples , 2014, Genome Biology.

[2]  R. Schwab,et al.  Reproductive risk factors and breast cancer subtypes: a review of the literature , 2014, Breast Cancer Research and Treatment.

[3]  Chris Sander,et al.  The molecular diversity of Luminal A breast tumors , 2013, Breast Cancer Research and Treatment.

[4]  C. Sotiriou,et al.  Luminal breast cancer: from biology to treatment , 2013, Nature Reviews Clinical Oncology.

[5]  S. Howell.  Advances in the treatment of luminal breast cancer , 2013, Current opinion in obstetrics & gynecology.

[6]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[7]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[8]  A. Luini,et al.  Outcome of special types of luminal breast cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  B. Pockaj,et al.  The Impact of Obesity on Breast Cancer: A Retrospective Review , 2012, Annals of Surgical Oncology.

[10]  S. Leung,et al.  CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer , 2012, Breast Cancer Research.

[11]  R. Prentice,et al.  Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. , 2011, Journal of the National Cancer Institute.

[12]  Victoria L. Cafourek,et al.  Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. , 2011, Journal of the National Cancer Institute.

[13]  M. Ewertz,et al.  Effect of obesity on prognosis after early-stage breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  K. Horwitz,et al.  Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers , 2011, Breast Cancer Research and Treatment.

[15]  Päivi Heikkilä,et al.  Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies , 2010, PLoS medicine.

[16]  K. Horwitz,et al.  Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts , 2008, Proceedings of the National Academy of Sciences.

[17]  Samuel Leung,et al.  Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.

[18]  C. Perou,et al.  Epidemiology of basal-like breast cancer , 2008, Breast Cancer Research and Treatment.

[19]  Douglas Macmillan,et al.  Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. , 2006, European journal of cancer.

[20]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[21]  I. Ellis,et al.  Expression of luminal and basal cytokeratins in human breast carcinoma , 2004, The Journal of pathology.

[22]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.